SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-17-143143
Filing Date
2017-04-27
Accepted
2017-04-27 16:35:55
Documents
9
Effectiveness Date
2017-04-27

Document Format Files

Seq Description Document Type Size
1 NOTICE AND ACCESS d366780ddefa14a.htm DEFA14A 31870
2 GRAPHIC g366780n1.jpg GRAPHIC 64728
3 GRAPHIC g366780n2.jpg GRAPHIC 7764
4 GRAPHIC g366780n3.jpg GRAPHIC 15156
5 GRAPHIC g366780n4.jpg GRAPHIC 8896
6 GRAPHIC g366780n5.jpg GRAPHIC 3338
7 GRAPHIC g366780n6.jpg GRAPHIC 4821
8 GRAPHIC g366780n7.jpg GRAPHIC 4821
9 GRAPHIC g366780n8a.jpg GRAPHIC 1500
  Complete submission text file 0001193125-17-143143.txt   186895
Mailing Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752
Business Address 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA 01752 (508) 767-3861
RXi Pharmaceuticals Corp (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36304 | Film No.: 17789619
SIC: 2834 Pharmaceutical Preparations